Understanding Postmarketing Requirements and Commitments for CYP3A-mediated Drug-drug Interactions: An Analysis of FDA-approved Drugs from 2015 to 2024

Presented at the 127th ASCPT International Meeting, March 2026
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, and Isabelle Ragueneau-Majlessi

2026 ASCPT Poster Presentation – CYP3A PMR/PMCs

Abstract

The objective of the present work was to review recent PMRs and PMCs related to CYP3A, the enzyme most often evaluated in post-marketing studies, to characterize the nature of the requests.